Amy Claxton, PhD
a:1:{i:0;s:65:"Clinical Development, Bristol Myers Squibb, Princeton, New Jersey";}
Original Research
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
February 26, 2025
In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
Original Research
Long-Term Safety of Aripiprazole Lauroxil
August 18, 2020
Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
